Drug intelligence / Profile preview

OCT102

Development stage: Unknown
Lead developer: Octagon Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes

Overview

OCT102 is a drug candidate developed by Octagon Therapeutics. It is designed to suppress the secretion of inflammatory cytokines involved in certain inflammatory diseases by acting on an undisclosed immune checkpoint, with its primary target being CD8. The drug is under investigation for use in dermatomyositis and potentially other autoimmune or inflammatory conditions. As of the latest available information, OCT102 remains in the discovery phase of development and has not yet entered clinical trials[5].

Targets

CD8A (CD8 alpha/beta Coreceptor)

Beyond the preview

Go deeper on OCT102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OCT102.

Explore the full profile